|Mr. Howard W. Robin||CEO, Pres & Director||2.24M||N/A||1953|
|Mr. Gilbert M. Labrucherie||Sr. VP, CFO & COO||1.54M||N/A||1972|
|Mr. Mark A. Wilson||Sr. VP, Gen. Counsel & Sec.||780.49k||N/A||1972|
|Dr. Jonathan Zalevsky||Chief R&D Officer||1.19M||N/A||1975|
|Mr. John P. Northcott||Sr. VP & Chief Commercial Officer||1.16M||N/A||1978|
|Ms. Jillian B. Thomsen||Sr. VP of Fin. & Chief Accounting Officer||N/A||N/A||1966|
|Ms. Jennifer Ruddock||Sr. VP of Strategy & Corp. Affairs||N/A||N/A||N/A|
|Dr. Mary Tagliaferri||Sr. VP & Exec. Clinical Fellow||N/A||N/A||1966|
|Dr. Brian L. Kotzin||Interim Chief Medical Officer & Head of Devel.||N/A||N/A||1949|
|Dr. Kevin Brodbeck||Sr. VP of Manufacturing||N/A||N/A||N/A|
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of non-small cell lung cancer and immuno-oncology; and phase 1B clinical trial to treat COVID-19.It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat locally advanced or metastatic solid tumor malignancies, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Nektar Therapeutics’s ISS Governance QualityScore as of June 1, 2021 is 3. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 3; Compensation: 5.